milvexian
bms
['factor xi', 'axiomatic', 'milvexian', '$bmy']
$bmy late-breaking results from phase 2 axiomatic-ssp study of milvexian, an investigational oral factor xia inhibitor, show favorable antithrombotic profile in combination with dual antiplatelet therapy 
This is an automated account sharing new press releases in real time from https://t.co/7iCFuj68H6